Safety and Efficacy of Stereotactic Radiosurgery and Adjuvant Bevacizumab in Patients With Recurrent Malignant Gliomas
- 1 April 2012
- journal article
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 82 (5), 2018-2024
- https://doi.org/10.1016/j.ijrobp.2010.12.074
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade GliomasJournal of Clinical Oncology, 2010
- Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant GliomasInternational Journal of Radiation Oncology*Biology*Physics, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Stereotactic radiosurgery for glioblastoma: retrospective analysisRadiation Oncology, 2009
- Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant GliomasClinical Cancer Research, 2008
- Reirradiation Tolerance of the Human BrainInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Bevacizumab Plus Irinotecan in Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2007
- Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth FactorCancer Research, 2006
- Survival in patients with recurrent glioma as a measure of treatment efficacy: Prognostic factors following nitrosourea chemotherapyEuropean Journal Of Cancer, 1994
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993